Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to TradeZacks Investment Research • 04/24/25
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use SettingBenzinga • 04/11/25
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster DrugInvestors Business Daily • 04/11/25
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 04/10/25
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDPGlobeNewsWire • 04/08/25
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?Zacks Investment Research • 03/17/25
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual MeetingGlobeNewsWire • 03/07/25
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor ImminentSeeking Alpha • 02/27/25
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 02/27/25
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025GlobeNewsWire • 02/20/25
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits HighsInvestors Business Daily • 02/19/25
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 12/27/24
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesGlobeNewsWire • 11/20/24